Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALax-C study of PBKR03 in early infantile Krabbe disease
NL-OMON51988Phase 2Not yet recruiting
- Sponsor
- Passage Bio
- Start
- Jun 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PBKR03 in Krabbe disease, sponsored by Passage Bio. Primary endpoint: Safety and tolerability of PBKR03. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
PBKR03
03
Conditions
Krabbe disease
Beyond the preview
Go deeper on NL-OMON51988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51988.